Skip to main content
    G

    GeneDx Holdings Corp. (WGS)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $51.02
    -1.35 (-2.58%)

    Market Cap: $1.57B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    GeneDx Holdings Corp. (WGS) Financials: Revenue, Profit and Cash Flow

    Updated Nov 9, 2026. Financial statements from company filings, amounts in US dollars.

    GeneDx Holdings reported revenue of $427.54M for the fiscal year ended Dec 31, 2025, up 40.0% from the year before. That year, net income was -$21.02M with a net margin of -4.9%, operating cash flow was $33.28M and free cash flow was $14.26M. The quarter ended Sep 30, 2026 had revenue of $123.10M and net income of -$12.33M.

    Revenue and Margins

    The operating margin was -3.1% in the fiscal year ended Dec 2025, the highest of the 4 years shown with an operating margin. Over the 6 years to Dec 2025, revenue grew from $196.17M, a compound annual rate of 13.9%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$427.54M+40.0%69.7%-3.1%-4.9%
    Dec 2024$305.45M+50.8%63.6%-7.6%-17.1%
    Dec 2023$202.57M-13.7%44.4%-89.2%-86.8%
    Dec 2022$234.69M+10.6%-11.4%-284.5%-233.9%
    Dec 2021$212.19M+18.3%-7.8%-210.3%-115.6%
    Dec 2020$179.32M-8.6%2.2%-134.9%-134.6%
    Dec 2019$196.17MN/A42.2%-15.5%-15.1%
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$427.54M$305.45M$202.57M$234.69M$212.19M$179.32M$196.17M
    Cost of revenue$129.37M$111.05M$112.56M$261.44M$228.80M$175.30M$113.39M
    Gross profit$298.17M$194.40M$90.01M-$26.75M-$16.60M$4.03M$82.78M
    Research and development$72.03M$45.72M$58.27M$86.20M$105.16M$72.70M$34.91M
    Operating income-$13.08M-$23.21M-$180.60M-$667.65M-$446.15M-$241.99M-$30.41M
    Net income-$21.02M-$52.29M-$175.77M-$548.98M-$245.39M-$241.34M-$29.70M
    EBITDA$6.63MN/A-$144.07M-$538.06M-$220.76M-$227.64M-$23.50M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$123.10M$114.44M$102.25M$120.99M$116.74M$102.69M$87.11M$95.64M$76.87M$70.51M$62.42M$57.42M
    Gross profit$86.06M$78.24M$68.21M$84.27M$84.53M$70.90M$58.48M$66.20M$47.83M$42.95M$37.41M$30.75M
    Operating income-$10.43M-$17.45M-$57.47M-$14.23M-$3.25M$8.96M-$4.55M$8.81M-$7.78M-$10.58M-$13.66M-$25.64M
    Net income-$12.33M-$17.74M-$63.32M-$17.67M-$7.63M$10.81M-$6.53M$5.44M-$8.31M-$29.17M-$20.24M-$25.77M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $57.12M by $47.88M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$523.71M$419.38M$418.76M$490.94M$554.09M$251.64MN/A
    Current assets$268.29M$197.97M$182.34M$212.62M$483.54M$174.11M$163.81M
    Cash and equivalents$105.00M$85.21M$99.68M$123.93M$400.57M$108.13MN/A
    Total liabilities$215.53M$174.13M$190.74M$237.24M$165.99M$247.25MN/A
    Short-term debt$8.95M$3.34M$4.14M$10.87M$3.42M$3.51MN/A
    Long-term debt$48.18M$51.91M$52.69M$6.25M$11.00M$18.97MN/A
    Shareholder equity$308.18M$245.25M$228.02M$253.71M$388.10M-$330.05MN/A
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$526.48M$481.49M$506.30M$570.19M$493.90M$463.86M$446.43M$419.38M$408.84M$389.10M$394.53M$418.76M
    Total liabilities$281.80M$237.26M$252.18M$262.01M$201.64M$186.73M$189.03M$174.13M$204.34M$195.06M$187.31M$190.74M
    Cash and equivalents$96.14M$60.32M$93.92M$105.00M$95.97M$74.12M$99.70M$85.21M$57.89M$56.08M$83.67M$99.68M
    Shareholder equity$244.69M$244.22M$254.12M$308.18M$292.26M$277.13M$257.40M$245.25M$204.50M$194.04M$207.22M$228.02M
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 42.8% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow$33.28M-$28.50M-$180.15M-$319.15M-$190.43M-$93.13M-$18.73M
    Capital expenditures$19.02M$5.49M$5.71M$14.32M$20.79M$31.97M$15.46M
    Free cash flow$14.26M-$33.99M-$185.86M-$333.48M-$211.22M-$125.10M-$34.18M
    Dividends paidN/AN/AN/AN/A$51.76M$0$0
    Investing cash flow-$61.52M-$30.13M-$43.73M-$141.33M-$20.79M-$31.97M-$15.46M
    Financing cash flow$48.02M$44.16M$186.24M$197.31M$493.73M$129.06M$148.01M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$10.60M-$28.98M-$32.41M-$3.09M$15.77M$10.42M$10.18M-$3.18M-$4.39M-$4.50M-$16.41M-$29.86M
    Capital expenditures$5.22M$10.11M$6.45M$4.35M$6.17M$2.37M$6.13M$3.05M$646.00K$1.35M$443.00K$2.38M
    Free cash flow-$15.82M-$39.09M-$38.86M-$7.44M$9.60M$8.05M$4.05M-$6.23M-$5.04M-$5.86M-$16.86M-$32.23M
    Last 12 quarters

    Frequently Asked Questions About WGS

    What is GeneDx Holdings' annual revenue?

    GeneDx Holdings reported revenue of $427.54M for the fiscal year ended Dec 31, 2025.

    How fast is GeneDx Holdings' revenue growing?

    Revenue was up 40.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 22.1%.

    Is GeneDx Holdings profitable?

    No. GeneDx Holdings reported net income of -$21.02M for the fiscal year ended Dec 31, 2025, with a net margin of -4.9%.

    How much free cash flow does WGS generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $33.28M minus capital expenditures of $19.02M produced free cash flow of $14.26M.

    How much debt does GeneDx Holdings have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $48.18M, short-term debt of $8.95M and cash and equivalents of $105.00M.